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Achieving evidence for the management of 
arthralgia at risk for RA. Response to: ‘The cost 
of arthralgia ‘pretreatment’ to prevent 
rheumatoid arthritis’ by Rothschild
We read the letter from Rothschild with interest.1 We agree that 
we need more data and better evidence on: (1) how to determine 
the risk of patients with arthralgia progressing to ‘true RA’ and 
on (2) whether or not Disease Modifying AntiRheumatic Drug 
(DMARD) treatment is better than placebo in this phase. Both 
points were discussed in our Viewpoint.2 Cost–benefit analyses 
can only be performed afterwards.
Rothschild seems to agree with us not to condone treating 
patients presenting with arthralgia with DMARDs, pending 
further evidence. Still, there are different opinions in the field. 
This is illustrated by a recent study from the UK, in which rheu-
matologists were asked about their management in clinical prac-
tice of arthralgia patients with positive anti- cyclic citrullinated 
peptide antibodies antibodies and signs of synovitis on power 
Doppler in at least one joint, but in the absence of clinically 
apparent arthritis. Seventy- one per cent of consultants said to 
start DMARD treatment, 16% would treat with glucocorticoids 
only, 8% considered inclusion in a clinical trial and only 3% 
replied to wait and see without immediate initiation of DMARD 
treatment.3
We believe it may be harmful if the rheumatic field gets 
too comfortable with initiating DMARD treatment already in 
arthralgia patients with a certain risk of developing true rheu-
matoid arthritis (RA) without solid proof. Such a behaviour 
hampers the course of observational studies to properly deter-
mine the risk of RA in individual patients. Hindering the natural 
course of patients in observational studies with DMARD treat-
ment means that we will never be able to know which patients 
are being overtreated. Importantly, the regular use of DMARDs 
in this setting may also hinder the inclusion of arthralgia patients 
in ongoing and future placebo- controlled trials, as this will then 
be considered increasingly counterintuitive or unethical because 
physicians in daily clinical practice may increasingly consider 
DMARD treatment standard of therapy.
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